Skip to main content

Table 2 Type and risks of clinical events included in the model (reported per 100 patient/years)

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Events Apixaban Warfarin Source
Ischemic stroke risk by CHADS2    [15]
Mean 0,962 1,064  
CHADS2 score 0 0,521 0,458  
CHADS2 score 1 0,521 0,458  
CHADS2 score 2 0,950 0,934  
CHADS2 score 3 1,534 1,944  
CHADS2 score 4 1,534 1,944  
CHADS2 score 5 1,534 1,944  
CHADS2 score 6 1,534 1,944  
Systemic embolism 0.090 0.100 [12]
Hemorrhagic stroke and Intracranial Hemorrhage 0.330 0.800 [12]
Other major bleeding 1.790 2.270 [12]
Clinically Relevant Non-Major Bleeding 2.083 2.995 [15]
Myocardial Infarction 0,530 0,610 [12]
Other hospitalizations due to cardiovascular disease 10.460 10.460 [15]
Recurrent ischemic stroke 4.103 4.103 [43]
Recurrent hemorrhagic stroke 3.00 3.00 [43]